News | March 04, 2008

First Implant of CRT-D with New Platform Completed

February 5, 2008 - Doctors completed the first implant of Boston Scientific’s COGNIS cardiac resynchronization therapy defibrillator (CRT-D), which reportedly represents an entirely new platform to treat heart failure.

The COGNIS was part of a multi-year research and development effort to build a devices that offers extended longevity and a number of new features to manage heart failure patients. One such feature is the SmartDelay, which is said to quickly proposes programmable device settings and enable clinicians to tailor individualized pacing therapy for their patients.

The COGNIS CRT-D is small and thinn with high-energy at 32.5 cc, and less than 10 mm thick. The COGNIS CRT-D also offers SafetyCore, a feature that in the unlikely event of a system error is designed to provide lifesaving shock therapy and basic pacing functionality.

Key features of the COGNIS CRT-D include:

- Bi-V Trigger: designed to help physicians manage heart failure patients with frequent atrial arrhythmias
- Electronic Repositioning: provides physicians with the ability to electronically select between six different configurations for stimulating the left side of the heart even after implant, which could help avoid an additional surgical procedure, the company says.
- Left Ventricle only pacing: this feature provides physicians with an additional pacing option for CRT patients

For more information: www.bostonscientific.com

Related Content

Medtronic Begins Pilot Study of Investigational Extravascular ICD System
News | Implantable Cardioverter Defibrillator (ICD) | August 09, 2018
Medtronic plc announced the start of a pilot study of its investigational Extravascular Implantable Cardioverter...
ICD Placements Not Meeting Medicare Coverage Criteria Decline After Overuse Investigation Announced
Feature | Implantable Cardioverter Defibrillator (ICD) | July 11, 2018
Placement of implantable cardioverter defibrillators (ICDs) not meeting Centers for Medicare and Medicaid Services (CMS...
New Tool Predicts Benefits and Risks of Implantable Defibrillator for Heart Failure Patients
News | Implantable Cardioverter Defibrillator (ICD) | July 02, 2018
University of Washington (UW) Medicine cardiologists have developed a tool to predict which heart-failure patients...
Real-World Data Demonstrates Success Of Smart Pass Filter on Boston Scientific S-ICD System
News | Implantable Cardioverter Defibrillator (ICD) | May 16, 2018
Boston Scientific announced results from an analysis of the LATITUDE database evaluating the successful reduction of...
Online Message Board Advice on ICDs Reflects Inaccuracies
News | Implantable Cardioverter Defibrillator (ICD) | April 13, 2018
April 13, 2018 — Medical advice about implanted cardiac defibrillators obtained via an online message board appears t
Biotronik U.S. to Distribute Aziyo ECM Envelopes
News | Implantable Cardioverter Defibrillator (ICD) | April 12, 2018
Biotronik U.S. and Aziyo announced a strategic agreement allowing Biotronik to distribute Aziyo's CanGaroo...
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD) | September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD) | September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD) | July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD) | June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
Overlay Init